Research Analysts Set Expectations for PVLA FY2025 Earnings

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for shares of Palvella Therapeutics in a research note issued on Wednesday, November 12th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($3.60) for the year, down from their previous forecast of ($3.38). HC Wainwright currently has a “Buy” rating and a $190.00 target price on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ Q4 2025 earnings at ($0.98) EPS, FY2026 earnings at ($3.28) EPS, FY2027 earnings at ($3.62) EPS, FY2028 earnings at ($2.34) EPS and FY2029 earnings at $0.40 EPS.

Other research analysts have also issued reports about the stock. Lifesci Capital initiated coverage on shares of Palvella Therapeutics in a research note on Monday, August 4th. They set an “outperform” rating and a $90.00 price objective on the stock. Stifel Nicolaus boosted their price target on Palvella Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Oppenheimer reaffirmed an “outperform” rating on shares of Palvella Therapeutics in a research report on Tuesday. Truist Financial increased their price objective on shares of Palvella Therapeutics from $80.00 to $105.00 and gave the company a “buy” rating in a research report on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Palvella Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $104.50.

Palvella Therapeutics Trading Down 1.3%

Shares of PVLA opened at $80.50 on Friday. The company has a market cap of $890.33 million, a price-to-earnings ratio of -21.24 and a beta of -0.05. Palvella Therapeutics has a 1-year low of $11.17 and a 1-year high of $85.03. The company’s fifty day simple moving average is $68.24 and its 200 day simple moving average is $44.25.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Tuesday, November 11th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.18).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Royce & Associates LP bought a new position in shares of Palvella Therapeutics during the first quarter worth approximately $2,002,000. Frazier Life Sciences Management L.P. grew its position in Palvella Therapeutics by 5.5% during the first quarter. Frazier Life Sciences Management L.P. now owns 690,012 shares of the company’s stock worth $19,313,000 after buying an additional 36,120 shares in the last quarter. AWM Investment Company Inc. bought a new position in Palvella Therapeutics during the 1st quarter worth $1,943,000. Millennium Management LLC acquired a new position in Palvella Therapeutics in the 1st quarter valued at $7,553,000. Finally, Goldman Sachs Group Inc. acquired a new position in Palvella Therapeutics in the 1st quarter valued at $533,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.